Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Gandara

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancerD R Gandara, M W DeGregorio, H Wold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
RB status as a determinant of response to UCN-01 in non-small cell lung carcinomaP C Mack, D R Gandara, C Bowen, et al.
Cancer|August 10, 1999
Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndromeM J Edelman, D R Gandara, F J Meyers, et al.
Clinical Pharmacology and Therapeutics|February 14, 2015
Innovative Clinical Trials: The LUNG-MAP StudyC E Steuer, V Papadimitrakopoulou, R S Herbst, et al.
Seminars in Oncology|August 1, 1992
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placeboD R Gandara, W H Harvey, G G Monaghan, et al.
Journal of the National Cancer Institute|May 10, 1989
Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimenD R Gandara, H Wold, E A Perez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology GroupK Kelly, L Lovato, P A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1995
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factorsM Roach, D R Gandara, H S Yuo, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observationsM W DeGregorio, D R Gandara, W M Holleran, et al.
Investigational New Drugs|September 20, 2001
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer ConsortiumK Margolin, J Longmate, T W Synold, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1986
High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancerD R Gandara, M W DeGregorio, H Wold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
RB status as a determinant of response to UCN-01 in non-small cell lung carcinomaP C Mack, D R Gandara, C Bowen, et al.
Cancer|August 10, 1999
Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndromeM J Edelman, D R Gandara, F J Meyers, et al.
Clinical Pharmacology and Therapeutics|February 14, 2015
Innovative Clinical Trials: The LUNG-MAP StudyC E Steuer, V Papadimitrakopoulou, R S Herbst, et al.
Seminars in Oncology|August 1, 1992
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placeboD R Gandara, W H Harvey, G G Monaghan, et al.
Journal of the National Cancer Institute|May 10, 1989
Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimenD R Gandara, H Wold, E A Perez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology GroupK Kelly, L Lovato, P A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1995
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factorsM Roach, D R Gandara, H S Yuo, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observationsM W DeGregorio, D R Gandara, W M Holleran, et al.
Investigational New Drugs|September 20, 2001
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer ConsortiumK Margolin, J Longmate, T W Synold, et al.
Pageof 9